Janux Therapeutics Management
Management criteria checks 4/4
Janux Therapeutics' CEO is David Campbell, appointed in Jun 2017, has a tenure of 7.42 years. total yearly compensation is $4.19M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.54% of the company’s shares, worth $15.14M. The average tenure of the management team and the board of directors is 2.3 years and 3.7 years respectively.
Key information
David Campbell
Chief executive officer
US$4.2m
Total compensation
| CEO salary percentage | 14.9% |
| CEO tenure | 7.4yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01
Janux Therapeutics: Buoyed By Buyout Speculation
Sep 01Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$44m |
| Mar 31 2024 | n/a | n/a | -US$56m |
| Dec 31 2023 | US$4m | US$625k | -US$58m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$67m |
| Dec 31 2022 | US$6m | US$550k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$8m | US$459k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$8m |
| Dec 31 2020 | US$812k | US$405k | -US$7m |
Compensation vs Market: David's total compensation ($USD4.19M) is below average for companies of similar size in the US market ($USD6.59M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Campbell (64 yo)
7.4yrs
Tenure
US$4,193,269
Compensation
Dr. David Campbell, Ph D serves as President, Chief Executive Officer and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therap...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$4.19m | 0.54% $ 15.1m | |
| Chief Technical Officer | 1.8yrs | US$1.61m | 0.098% $ 2.8m | |
| Chief Strategy Officer | 2.8yrs | US$1.74m | 0% $ 0 | |
| Vice President of Finance | less than a year | no data | no data | |
| Principal Accounting Officer & VP of Accounting | less than a year | no data | no data | |
| Chief Scientific Officer | less than a year | no data | 0.19% $ 5.3m | |
| General Counsel | 3.3yrs | no data | no data | |
| Chief Business Officer | 3.7yrs | no data | 0.13% $ 3.6m |
2.3yrs
Average Tenure
47.5yo
Average Age
Experienced Management: JANX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$4.19m | 0.54% $ 15.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.7yrs | US$173.01k | 0.13% $ 3.6m | |
| Chairperson | 3.2yrs | US$162.69k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.2yrs | US$166.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 3.7yrs | US$158.01k | 0.21% $ 6.0m | |
| Independent Director | 2.2yrs | US$164.77k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$172.07k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.7yrs
Average Tenure
61yo
Average Age
Experienced Board: JANX's board of directors are considered experienced (3.7 years average tenure).